AnaCardio raises USD 19 million to advance first-in-class drug candidate AC01 for heart failure – Reports positive results from phase 1b study of AC01 in patients with heart failure and reduced ejection fraction (HFrEF)
January 9, 2025, Stockholm, Sweden – AnaCardio, a clinical-stage biopharmaceutical company developing novel contractile agents to treat patients with heart failure today announced the completion of a USD 19 million (SEK 205 million) Series A extension financing round, co-led by Novo Holdings, Pureos Bioventures and Sound Bioventures. Current investors Flerie, Industrifonden, and Fredrik and Ann-Helene Ljungström, also participated to complete the round. The raised funds will be used to complete the phase 1b/2a GOAL-HF1 study, and to prepare and initiate start-up activities for the subsequent phase 2b study.
